Field
     It is expected to be used as medical drugs, more specifically as therapeutic agents for
     inflammatory diseases or autoimmune diseases.

Keywords
     TNFα receptor,  Antibody drug

Advantages
     The antibody drugs for treating rheumatic diseases have a huge market potential and it is
     possible for a single drug product to return over 500 billion yen. Consequently, competition is
     extremely fierce. With our new idea, we have successfully improved the stability of CDC and
     ADCC activity by obtaining the receptor to dually bind to the Fc portion of the antibody.

Abstract
A huge market has been formed with anti-IL6 and anti-TNFα antibodies used as antibody drug products for treating rheumatic diseases. Many applications that target the field of TNFα have been filed for patents, however, this invention was completed with the idea of effectively using TNFα by binding it to the Fc portion of the antibody to improve CDC and ADCC activity. No other patents have been found that focus on the receptor as ours does. We filed a provisional U.S. patent application (June 30, 2010). We will request an examination after filing the PCT application.

          


Inventor
     Prof. Yasuhiko Masuho et al.　(Tokyo University of Science)


Patent Publication No
     (APPLICATION NUMBER, FILING DATE)
     WO2011065407 *not yet published


Publication
Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y (2008) Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.  Mol Immunol 45:2752-2763

Internal file number
     LSP:92
     G2010-007

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: